论文部分内容阅读
在体外细胞水平上观察重组融合蛋白 (Fab/IFN αA)对乙型肝炎病毒 (HBV)基因表达的抑制作用。方法 :应用HBVDNA转染细胞系 (HepG2 .2 .15细胞 )作模型 ,通过固相放射免疫方法检测Fab/IFN αA作用后细胞上清液的HBsAg、HBeAg水平的变化 ,结合细胞存活率来评价其抗HBV作用 ,并与α 干扰素 (IFN αA)进行比较。结果 :经 12d作用 ,Fab/IFN αA在细胞存活率、对HBsAg、HBeAg抑制率均优于IFN αA ,尤其在 2 5 0 0～5 0 0 0IU/ml浓度下 ,其细胞存活率为 82 .41%～ 83.19% ,HBsAg抑制率 5 5 .5 5 %～ 6 8.18% ,HBeAg抑制率 45 .0 7%～ 48.5 5 % ,而相应浓度IFN αA的HBsAg、HBeAg抑制率均低于Fab/IFN αA (P <0 .0 1或P <0 .0 5 )。结论 :具有抗体的导向作用和IFN的抗病毒作用的Fab/IFN αA体外抗HBV作用优于IFN αA ,为进一步研制抗乙型病毒性肝炎的生物导向治疗的基因工程多肽类药物提供了依据。
The inhibitory effect of recombinant fusion protein (Fab / IFNαA) on hepatitis B virus (HBV) gene expression was observed at the cellular level in vitro. Methods: HBsAg-transfected cell line (HepG2.2.15 cells) was used as a model to detect the changes of HBsAg and HBeAg levels in the cell supernatant treated with Fab / IFNαA by solid-phase radioimmunoassay, and the cell viability was evaluated It has an anti-HBV effect and is compared with interferon alpha (IFN alpha A). Results: After 12 days, the cell viability of Fab / IFNαA was lower than that of IFNαA. The cell survival rate of Fab / IFNαA was 82% at the concentration of 25000 ~ 50000 IU / ml. 41% -83.19%, HBsAg inhibition rate 5.55% ~ 6 8.18%, HBeAg inhibition rate 45.077% ~ 48.5 5%, while the corresponding concentration of IFNαA HBsAg, HBeAg inhibition rates were lower than Fab / IFN αA (P <0. 01 or P <0. 05). Conclusion: The anti-HBV effect of Fab / IFNαA with anti-HBV and Fab-IFNαA in vitro is better than that of IFNαA. This study provides a basis for further development of genetically engineered peptides for bio-therapy of hepatitis B virus.